Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Active:	Yes
Cancer Type:	Colon/Rectal Cancer Lung Cancer Solid Tumor	NCT ID:	NCT05783622
Trial Phases:	Phase I	Protocol IDs:	EGFR-008-001 (primary) NCI-2023-02676
Eligibility:	18 - 100 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Janux Therapeutics
NCI Full Details:	http://clinicaltrials.gov/show/NCT05783622

Summary

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation
and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects
with advanced or metastatic carcinoma expressing EGFR.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.